Goldman Sachs’s Liminatus Pharma LIMN Stock Holding History
Bought
Maintained
Sold
Other funds holding LIMN
Goldman Sachs's LIMN Position: Q3 2026 in Review
Goldman Sachs sold out of Liminatus Pharma (LIMN) in Q3 2026, closing a stake of 804 shares — an estimated $4.44K sold.
Goldman Sachs first reported a position in LIMN in Q2 2026 and held it in 1 quarter. The position peaked at $4.44K in Q2 2026. 10 funds tracked by Wall St. Rank hold LIMN as of Q3 2026.
- Goldman Sachs reported no remaining Liminatus Pharma position as of Q3 2026 after selling out during the quarter.
- Goldman Sachs sold 804 Liminatus Pharma shares in Q3 2026, an estimated $4.44K.
- Goldman Sachs first reported a position in Liminatus Pharma in Q2 2026 and held it in 1 quarter.
- Goldman Sachs's Liminatus Pharma position peaked at $4.44K in Q2 2026.
- 10 funds tracked by Wall St. Rank held Liminatus Pharma as of Q3 2026.
Based on Goldman Sachs's 13F filing for Q3 2026, filed 16 Nov 2026.